Revlimid Fast Track Status Based On Randomized Trial Plan Later Skipped
This article was originally published in Pharmaceutical Approvals Monthly
Celgene was granted a fast track designation for Revlimid based on plans to conduct a randomized trial that it later put off until after FDA approval, review documents show
You may also be interested in...
An inadequate reproductive safety assessment of Celgene’s Revlimid was of central concern to FDA during its review of the myelodysplastic syndromes treatment and helped guide post-approval risk management requirements, review documents show.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011